Safety and tolerance of ENA 713 in Alzheimer's disease (AD)

Author： Cutler N.R.   Sramek J.J.   Anand R.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 382-383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD)

By Lukiw Walter J  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 255-271

Informa Healthcare

Access to resources Recommend Favorite

Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future

By Fazil Mohammad     Baboota Sanjula   Sahni Jasjeet K.   Ali Javed  

Journal of Drug Targeting, Vol. 20, Iss. 2, 2012-02 ,pp. : 97-113

Informa Healthcare

Access to resources Recommend Favorite

Galantamine shows sustained cognitive benefits in patients with Alzheimer's disease (AD)

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

ENaC Modulators and Renal Disease

By  

Current Molecular Pharmacology, Vol. 6, Iss. 1, 2013-03 ,pp. : 35-43

Bentham Science Publishers

Access to resources Recommend Favorite

Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity

By Ramrez-Exposito M.J.   Robert-Baudouy J.   Mayas M.D.   Garca M.J.   Ramrez M.   Martnez-Martos J.M.  

European Neuropsychopharmacology, Vol. 11, Iss. 5, 2001-10 ,pp. : 381-383

Elsevier

Access to resources Recommend Favorite